[Form 4] Ralph Lauren Corporation Insider Trading Activity

Rhea-AI Filing Summary

Vor Biopharma Inc. (VOR) – Form 144 insider sale filing

President & CEO Robert Ang has filed a Form 144 indicating his intent to sell 214,135 common shares through Morgan Stanley Smith Barney on or after 15 Jul 2025. The shares have an aggregate market value of $520,586, based on the filing’s reference price, and represent roughly 0.17 % of the company’s 124.96 million shares outstanding.

The filing also discloses that Ang has already disposed of approximately 722,916 shares in the past three months, generating gross proceeds of about $1.49 million. Combined, recent and proposed sales total nearly 0.75 % of outstanding shares.

Form 144 serves as a notice of proposed sales of restricted or control securities and does not guarantee execution. Nevertheless, multiple sales in a short period signal meaningful insider monetisation activity that investors often monitor as a sentiment indicator.

• Shares to be sold: 214,135
• Broker: Morgan Stanley Smith Barney, NY
• Past 3-month sales: 722,916 shares
• Total shares outstanding: 124,959,520

Insights

Securities Analyst

TL;DR – Insider plans to sell 214k shares after 723k recent disposals; modest % of float but directionally negative.

Form 144 filings rarely move markets, yet they provide early warning of potential insider selling pressure. Robert Ang’s latest notice follows a series of sales totalling roughly 723k shares since 30 Jun 2025. The proposed 214k-share block equates to 0.17 % of shares outstanding; combined with prior sales, insider supply could approach 0.75 % of the float. While small in absolute terms, the consistency of sales may be interpreted as a soft signal of insider sentiment. No information is provided about Ang’s remaining ownership or rationale, limiting deeper valuation impact assessment. Net effect: mildly negative for near-term perception, limited fundamental impact.

Corporate Governance Expert

TL;DR – Repeated CEO share disposals raise optics issues but remain below materiality thresholds.

Rule 144 requires disclosure for transparency; Ang’s compliance is positive for governance. That said, consecutive transactions within weeks can create optics of declining confidence. The sale size is well under 1 % of shares outstanding and unlikely to alter control dynamics. Investors should monitor Form 4 filings to gauge total remaining ownership and whether sales align with a pre-arranged 10b5-1 plan. Absent negative operational news, I classify the filing as not materially impactful but modestly negative for sentiment.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

JARRETT VALERIE B

(Last) (First) (Middle)

RALPH LAUREN CORPORATION

650 MADISON AVENUE

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RALPH LAUREN CORP [ RL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	07/11/2025		A		3.16(1)	A	$0(1)	5,499.84	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units of the Issuer's Class A Common Stock payable as a result of the payment of a cash dividend on the Issuer's Class A Common Stock. The restricted stock units are payable solely in shares of the Issuer's Class A Common Stock issued to the Reporting Person in respect of restricted stock units previously granted under the Issuer's 2019 Long-Term Stock Incentive Plan.

	/s/ Avery S. Fischer, Attorney-in-Fact for Valerie Jarrett	07/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many VOR shares does Robert Ang plan to sell under this Form 144?

The filing covers 214,135 common shares with an approximate market value of $520,586.

What percentage of Vor Biopharma’s shares outstanding does the planned sale represent?

The proposed block is about 0.17 % of the 124.96 million shares outstanding.

When can the shares be sold?

The approximate sale date listed is 15 July 2025.

How many shares has the CEO already sold in the past three months?

The filing lists approximately 722,916 shares sold between 30 Jun 2025 and 10 Jul 2025.

Which broker will handle the transaction?

Morgan Stanley Smith Barney LLC, Executive Financial Services, New York, NY.